title: [Lung cancer].
abstract: The five year survival rate of lung cancer patients is only 10% in Japan. The staging system of c-TNM is more important than p-TNM when deciding treatment modality for lung cancer. Compared to other solid cancers, neoadjuvant therapy in lung cancer treatment has a more important position. A clinical protocol study should be carried out with the idea of "intent to treat" and medical oncology will play a more important role in the treatment of lung cancer.
authors.affiliation: Dept. of Surgery II, Kyorin University School of Medicine, Tokyo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Goya
authors.forename: R
authors.initials: R
authors.lastname: Kawaji
authors.forename: Y
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: O
authors.initials: O
authors.lastname: Yanagida
authors.forename: T
authors.initials: T
authors.lastname: Sekihara
mesh_terms: D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D008197:Lymph Node Excision; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D011013:Pneumonectomy